ArticleDigestive diseases and sciences2026
Urinary Calprotectin Is Not a Reliable Surrogate of Fecal Calprotectin Levels in Adults and Children with Crohn's Disease.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFecal calprotectin (FCAL) is an established biomarker for monitoring intestinal inflammation in inflammatory bowel disease. However, fecal sampling can be socially unacceptable and inconvenient. Urinary calprotectin (UCAL) could potentially be a suitable surrogate marker of FCAL.
methodsLevels of FCAL and UCAL and C-reactive protein (CRP) were measured in samples from two different cohorts; a) in adults with active Crohn's disease (CD) receiving induction treatment with adalimumab and b) children with CD during early food re-introduction after successful treatment with exclusive enteral nutrition (EEN). In each cohort, participants were categorized based on their FCAL trajectories. Adults were classified as responders if FCAL decreased ≥ 50% after 12 weeks of treatment; otherwise, they were classified as non-responders. In children, a FCAL baseline rise > 100% during three weeks of food reintroduction, after EEN, was classified as having an FCAL increase. Children were classified as FCAL-stable if FCAL remained < 300 mg/kg throughout food reintroduction. FCAL, UCAL and CRP were also measured in healthy adults.
resultsA total of 364 paired stool and urine samples, and 100 blood samples were utilized from adults and children with CD. Changes in UCAL did not parallel changes in FCAL, neither in adults who were classed as FCAL responders after 12-weeks treatment with biologics, nor in pediatric patients who demonstrated an increase in FCAL, following completion of EEN and return to normal diet. UCAL did not correlate with either FCAL or CRP.
conclusionsUrinary calprotectin is not a useful biomarker of systemic or gut inflammation in patients with CD.
Indexed as
Identifiers
42020855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.